Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oesophagogastric junction. It evaluates the perioperative oxaliplatin with S-1 (SOX) combined H. pylori eradication versus oxaliplatin with S-1 in the management of H. pylori-positive locally advanced adenocarcinoma of the gastric and oesophagogastric junction (cT3/4a Nx or T2 N2/3, M0) , assessing their values and advantages.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyrazi świadomą zgodę na udział w badaniu
- •Potwierdzony zaawansowany rak żołądka badaniem endoskopowym
- •Wiek od 18 do 75 lat
- •Wykazana obecność bakterii H. pylori (wynik pozytywny z jednego z testów)
- •Ogólny stan zdrowia pozwalający na duże zabiegi chirurgiczne
- •Prawidłowe wyniki podstawowych badań krwi (liczba białych krwinek, hemoglobina, płytki krwi)
- •Prawidłowe wskaźniki wątroby i nerek
- •Oczekiwana przeżywalność co najmniej 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The Sixth Affiliated Hospital，Sun Yat-sen University
Guangzhou, China
Trial contact
Bin Zhong
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.